Assessment of microvascular alterations in patients with angina pectoris and no evidence of significant coronary artery disease

Assessment of microvascular alterations in patients with angina pectoris and no evidence of significant coronary artery disease - Glycocalyx perturbation in patients with microvascular angina pectoris

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37954

Enrollment

Registered

2010-12-29

Start date

2011-02-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: General: Subjects who want to participate in the study should be over 18 years of age and be able to give informed consent.;Patients with coronary artery disease: These patients should have proven coronary artery disease, defined as >=50% diameter stenosis objectified by coronary angiography. ;Patients with suspected small vessel disease: These patients should have a positive exercise ECG but no evidence of significant coronary artery disease on their coronary angiogram. ;The time between the coronary angiogram and the MR perfusion scan and OPS imaging cannot exceed one year. It can be reasonably expected that the status of the coronaries will not have changed significantly over this time period if the symptoms of angina have not changed. ;Healthy controls: These subjects must be free of angina pectoris or (a history of) coronary artery disease.

Exclusion criteria

Exclusion criteria: Patients:;General: - Age =III. ;Contraindication to adenosine side effects: - AV-block (2nd or 3rd degree). - Severe asthma. - COPD Gold IV.;General contra-indications to MR imaging - Non compatible metallic implant (vascular clip, neuro-stimulator, cochlear implant). - Pacemaker or ICD. - Claustrophobia. - Body weight >130 kg. Contraindication to MRI contrast agent: - Renal failure (GFR =50% diameter coronary stenosis objectified by coronary angiography or computed tomographic (CT) angiography. - Previous myocardial infarction. - Previous coronary revascularization.

Design outcomes

Primary

Measure	Time frame
- MR perfusion imaging during resting conditions and adenosine infusion in a) patients with proven coronary artery disease and b) patient with angina pectoris but without significant coronary artery lesions. - OPS imaging of the sublingual circulation to measure glycocalyx dimension and barrier function before and after sublingual NTG administration in a) patients with proven coronary artery disease, b) patient with angina pectoris but without significant coronary artery lesions, and c) healthy controls.	—

Measure

Time frame

- MR perfusion imaging during resting conditions and adenosine infusion in a) patients with proven coronary artery disease and b) patient with angina pectoris but without significant coronary artery lesions. - OPS imaging of the sublingual circulation to measure glycocalyx dimension and barrier function before and after sublingual NTG administration in a) patients with proven coronary artery disease, b) patient with angina pectoris but without significant coronary artery lesions, and c) healthy controls.

—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results